EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression

Rashmi Shah, Gopal P Pathak, John Fris, Mathieu Castonguay, Tanya Gillan, Michael D Carter, Zhaolin Xu

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Rashmi Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, QEII Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Canada, AstraZeneca Canada Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)Biomarkers, TumorHumansFemaleClass I Phosphatidylinositol 3-KinasesMaleDisease ProgressionErbB ReceptorsAgedMiddle AgedPrevalenceProto-Oncogene Proteins c-aktPrognosisIsocitrate Dehydrogenase

Stichwörter der Autor:innen

Clonal heterogeneityCoexisting mutationsDriver mutationNSCLCTumor evolution

Substanzen

KRAS protein, humanProto-Oncogene Proteins p21(ras)Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanErbB ReceptorsEGFR protein, humanProto-Oncogene Proteins c-aktAKT1 protein, humanBiomarkers, TumorIDH1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, QEII Health Sciences Centre and Dalhousie University, Halifax, NS, Canada.
  • Department of Pathology, QEII Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. Electronic address: zhaolin.xu@nshealth.ca.

Förderung

  • Roche Canada
  • AstraZeneca Canada Inc

Zitieren

APA

Shah, R., Pathak, G. P., Fris, J., Castonguay, M., Gillan, T., Carter, M. D., & Xu, Z. (2026). Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116936

Vancouver

Shah R, Pathak GP, Fris J, Castonguay M, Gillan T, Carter MD, et al. Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116936

BibTeX
@article{Shah2026,
  author = {Shah, Rashmi and Pathak, Gopal P and Fris, John and Castonguay, Mathieu and Gillan, Tanya and Carter, Michael D and Xu, Zhaolin},
  title = {Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116936}
}
Kostenlos starten →